Background:
Despite much evidence and clearly elucidated expert guidelines, VTE prophylaxis remains underutilized, resulting in significant morbidity, mortality, and economic burden. Fear of bleeding has been identified as a barrier to optimal adherence. We hypothesized that overestimation of bleeding risk is an impediment to compliance with ACCP recommendations for VTE prophylaxis. The IMPROVE trial developed a bleeding risk tool from the records of 11,000 patients admitted with a variety of medical illnesses. There were 3.2% bleeding events; 1.2% major bleeds. The derivation cohort revealed 11 independent risk factors, each assigned a point value corresponding to its contribution to bleeding. A summed score =7 was associated with clinically significant bleeding. Our objective was to calculate bleeding risk scores in patients at risk for VTE but without orders for pharmacologic prophylaxis—potentially due to perceived risk of bleeding.
Methods:
Patients for this study were identified from a previously conducted hospital wide cross–sectional quality improvement study of 1,143 patients admitted to medical and surgical services. We included medical patients (1) without orders for pharmacological prophylaxis, (2) documented as contraindicated, and (3) ordered for mechanical prophylaxis alone. Charts were reviewed retrospectively to calculate the IMPROVE risk score. We used the online calculator for prediction of bleed risk. We excluded patients as follows: four with LOS = 1; four for low risk status, four with active bleed at admission; two with documented plan for palliative care; one with surgery in prior 3 months. Reviewers were trained to abstract clinical and demographic information by comparing their first 20 charts.
Results:
In this pilot study, 47 patients met inclusion criteria: 38.3% males, mean age 70.3 years (SD = 16.3). The most prominent admitting diagnosis was malignancy (25.5%; 38.3% of the total had a malignancy) followed by nonmalignant hematological disorders (12.8%). The mean IMPROVE point score was 4.5 (SD = 2.4), with 25 patients (74.5%) scoring below 7. The mean risk of major bleed = 1.04% (SD = 1.2) and the mean risk of clinically significant bleed= 2.8% (SD = 2.2). There was no statistically significant difference between bleeding risk scores for patients documented as contraindicated for pharmacologic prophylaxis compared to patients with no documentation or orders.
Conclusions:
Hesitation to order anticoagulant agents may derive from concerns about bleeding. We found that a significant proportion of patients either without orders for or documented as contraindicated for prophylaxis, had IMPROVE bleeding risk scores less than 7. Adding the IMPROVE bleeding risk could assist in estimating the risk benefit ratio and consequently may raise adherence. Future studies should capture providers’ rationale for withholding pharmacologic prophylaxis and prospectively evaluate the IMPROVE tool.